Latest research
Latest corporate research
Latest tax enhanced reviews
Subscribe now
What we do
Investment research services
Tax enhanced research services
Bespoke consulting services
About Hardman & Co.
Case Studies
Our team
News & events
Contact us
Twitter icon
Created with Sketch.
Latest corporate investment research
Detailed company analysis created specifically for investors
Latest tax enhanced research
Product reports for investors and advisors
Subscribe now
Receive our latest research as soon as it is published
Investment Research & Analysis
Detailed company analysis created for specifically for investors
Tax Enhanced Services
Product reports for investors and advisors
Bespoke Services
Services for clients with specific needs
About Hardman & Co.
We are the longest-established commissioned research provider. Read our story
Case Studies
We help a wide range of clients with different needs. Read what they say about us
Our Team
Meet the Hardman & Co team members
Latest Update
Our research can still be accessed for free under MIFID II.
Find out more >
All sectors
Agriculture
Building & Construction
Consumer
Financials
Industrial
Investment Companies
Life Sciences
Media
Mining
Oil & Gas
Property
Services
Technology
Utilities
list companies
City of London Investment Group
Financials
Market bounce gives FUM bounce
By
Dr Brian Moretta
17 Apr 2019
Advanced Oncotherapy
Life Sciences
Preparing for commercialisation
By
Dr Martin Hall
16 Apr 2019
Stay up-to-date with the latest research
Sign up to our newsletter
ValiRx
Life Sciences
VAL401 is going forward
By
Dr Martin Hall
15 Apr 2019
Tissue Regenix
Life Sciences
Expanded GPO coverage secured
By
Dr Martin Hall
10 Apr 2019
Genedrive Plc
Life Sciences
First commercial sales in new focus area: bio-threats
By
Dr Dorothea Hill
08 Apr 2019
Non-Standard Finance
Financials
Reading the runes: strong, controlled growth
By
Mark Thomas
05 Dec 2018
Redx Pharma
Life Sciences
RXC006: first anti-fibrosis development candidate
By
Dr Martin Hall
30 Nov 2018
Volta Finance
Financials
November 2018 Monthly
By
Mark Thomas
01 Nov 2018
Primary Health Properties
Property
Growing the footprint; optimising income and NAV
By
Mike Foster
29 Oct 2018
Volta Finance
Financials
October 2018 Monthly
By
Mark Thomas
03 Oct 2018
Allergy Therapeutics plc
Life Sciences
2018 full-year results: solid growth
By
Dr Martin Hall
27 Sep 2018
1
2
3
...
13
Next